Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Acting Commissioner Von Eschenbach Brings Capitol Hill Clout – Gottlieb

This article was originally published in The Tan Sheet

Executive Summary

FDA Acting Commissioner Andrew von Eschenbach's "clout on the Hill" could temper the perceived weakness usually associated with acting status, according to Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD
Advertisement

Related Content

Waxman Uses Plan B, FDA Acting Head To Spotlight Conflict-Of-Interest Bill
Waxman Uses Plan B, FDA Acting Head To Spotlight Conflict-Of-Interest Bill
Waxman Uses Plan B, FDA Acting Head To Spotlight Conflict-Of-Interest Bill
Von Eschenbach Likely To Put FDA Critical Path Initiative Back On Track
Von Eschenbach Likely To Put FDA Critical Path Initiative Back On Track
Acting FDA Head Von Eschenbach Takes A Step Back At NCI

Topics

Advertisement
UsernamePublicRestriction

Register

PS098715

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel